Yusuke Sato

Dr. Yusuke Sato

Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo 060-0812, Japan
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
Yusuke SatoYusuke Sato
Yusuke Sato
KHKazuki Hashiba
Kazuki Hashiba
KSKosuke Sasaki
Kosuke Sasaki
MMMasatoshi Maeki
Masatoshi Maeki
MTManabu Tokeshi
Manabu Tokeshi
HHHideyoshi Harashima
Hideyoshi Harashima

1 September 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
NSNour Shobaki
Nour Shobaki
Yusuke SatoYusuke Sato
Yusuke Sato
YSYuichi Suzuki
Yuichi Suzuki
NONana Okabe
Nana Okabe
HHHideyoshi Harashima
Hideyoshi Harashima

1 March 2016 in Journal of Controlled Release
Verified
Journal Article
Open access
SWShota Warashina
Shota Warashina
TNTakashi Nakamura
Takashi Nakamura
Yusuke SatoYusuke Sato
Yusuke Sato
YFYuki Fujiwara
Yuki Fujiwara
MHMamoru Hyodo
Mamoru Hyodo
HHHideyoshi Harashima
Hideyoshi Harashima
Applying small interfering RNA (siRNA) to dendritic cell (DC) based therapy represents a potential candidate for cancer immunotherapy. However, delivering siRNA to DCs is a challenging issue for non-viral vectors. To date, only viral vectors have achieved efficient gene silencing in DCs. We report herein that a novel cationic lipid, YSK12-C4, when loaded in a nanoparticle with siRNA (YSK12-C4 multifunctional envelope type nano device [YSK12-MEND]), greatly facilitated gene silencing in mouse DCs. The use of the YSK12-MEND resulted in a gene silencing efficiency in excess of 90%, with a median effective dose (ED50) of 1.5nM, whereas the maximum gene silencing efficiency of Lipofectamine RNAiMAX was less than 60% and the ED50 was 25nM. Furthermore, suppressor of cytokine signaling 1, an immune suppressive molecule in DCs, silenced in the mouse DC by the YSK12-MEND showed a drastic enhancement in cytokine production, resulting in the significant suppression of tumor growth when it was applied to DC-based therapy against a mouse lymphoma. These results clearly indicate that YSK12-MEND overcomes the obstacle associated with non-viral vectors and can be considered to be a promising non-viral vector for siRNA delivery to DCs, thus accelerating DC-based therapies with siRNA.

1 June 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
Yusuke SatoYusuke Sato
Yusuke Sato
YKYoshiyuki Kinami
Yoshiyuki Kinami
KHKazuki Hashiba
Kazuki Hashiba
HHHideyoshi Harashima
Hideyoshi Harashima

10 May 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
KHKazuki Hashiba
Kazuki Hashiba
MTMasamitsu Taguchi
Masamitsu Taguchi
SSSachiko Sakamoto
Sachiko Sakamoto
AOAyaka Otsu
Ayaka Otsu
YMYoshiki Maeda
Yoshiki Maeda
Yusuke SatoYusuke Sato
Yusuke Sato
Lipid nanoparticles (LNPs) have emerged as promising platforms for efficient in vivo mRNA delivery owing to advancements in ionizable lipids. However, maintaining the thermostability of mRNA/LNP systems remains challenging. While the importance of only a small amount of lipid impurities on mRNA inactivation is clear, a fundamental solution has not yet been proposed. In this study, we investigate an approach to limit the generation of aldehyde impurities that react with mRNA nucleosides through the chemical engineering of lipids. We demonstrated that piperidine-based lipids improve the long-term storage stability of mRNA/LNPs at refrigeration temperature as a liquid formulation. High-performance liquid chromatography analysis and additional lipid synthesis revealed that amine moieties of ionizable lipids play a vital role in limiting reactive aldehyde generation, mRNA–lipid adduct formation, and loss of mRNA function during mRNA/LNP storage. These findings highlight the importance of lipid design and help enhance the shelf-life of mRNA/LNP systems.

1 February 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
YSYuichi Suzuki
Yuichi Suzuki
HOHaruno Onuma
Haruno Onuma
RSRisa Sato
Risa Sato
Yusuke SatoYusuke Sato
Yusuke Sato
AHAkari Hashiba
Akari Hashiba
HHHideyoshi Harashima
Hideyoshi Harashima